Diosmetin - CAS 520-34-3
Catalog number: B0084-093599
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C16H12O6
Molecular Weight:
300.266
COA:
Inquire
Targets:
Cytochrome P450
Description:
Diosmetin is a flavonoid that inhibits cytochrome P450 (CYP) isoforms 1A1 and 1B1 in human liver microsomes (Ki values of 89 and 16 nM, respectively). It exhibits anti-mutagenic and anti-allergic properties.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-093599 5 g $189 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Brife Description:
CYP1A1 inhibitor
Purity:
≥ 98%
Appearance:
Pale Yellow to Yellow Solid
Synonyms:
Diosmin EP Impurity F; Luteolin 4'-methyl ether; 5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one; 4'-Methylluteolin; Salinigricoflavonol
MSDS:
Inquire
Melting Point:
>225°C (dec.)
InChIKey:
MBNGWHIJMBWFHU-UHFFFAOYSA-N
InChI:
InChI=1S/C16H12O6/c1-21-13-3-2-8(4-10(13)18)14-7-12(20)16-11(19)5-9(17)6-15(16)22-14/h2-7,17-19H,1H3
Canonical SMILES:
COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O
1.Effects of Various 5,7-Dihydroxyflavone Analogs on Adipogenesis in 3T3-L1 Cells.
Nishina A1, Ukiya M, Fukatsu M, Koketsu M, Ninomiya M, Sato D, Yamamoto J, Kobayashi-Hattori K, Okubo T, Tokuoka H, Kimura H. Biol Pharm Bull. 2015;38(11):1794-800. doi: 10.1248/bpb.b15-00489.
We studied the effects of twelve 5,7-dihydroxyflavone analogs on adipogenesis in 3T3-L1 cells. Among the compounds, luteolin, diosmetin, and chrysoeriol partly inhibited adipogenesis by blocking the accumulation of triacylglycerol in the cells. Conversely, tricetin facilitated triacylglycerol accumulation in the cells. The induction of lipogenesis or lipolysis may depend on the number and bonding position of hydroxyl or methoxy groups on the B ring of 5,7-dihydroxyflavone. The mRNA expression levels of adipogenic and lipogenic genes were suppressed by luteolin treatment in the cells, while the mRNA levels of lipolytic genes were not affected. However, the expression levels of the adipogenic, lipogenic, and lipolytic genes, except for adipocyte protein 2 (aP2), were not affected by the addition of tricetin. Moreover, luteolin suppressed glucose transporter type 4 (GLUT4) gene and protein levels. These results indicate that luteolin decreased triacylglycerol levels in 3T3-L1 cells during adipogenesis through the suppression of adipogenic/lipogenic and GLUT4 genes and GLUT4 protein.
2.Diosmetin inhibits the metastasis of hepatocellular carcinoma cells by downregulating the expression levels of MMP‑2 and MMP‑9.
Liu J1, Wen X1, Liu B1, Zhang Q1, Zhang J1, Miao H1, Zhu R1. Mol Med Rep. 2016 Mar;13(3):2401-8. doi: 10.3892/mmr.2016.4872. Epub 2016 Feb 5.
Hepatocellular carcinoma (HCC) is one of the most malignant types of tumor worldwide with a high rate of mortality. Diosmetin (DIOS) exhibits various activities, including anticancer activities. However, the role of DIOS in the metastasis of HCC, and its underlying molecular mechanism, remain to be fully elucidated. In the present study, the antimetastatic effects of DIOS were investigated in SK‑HEP‑1 and MHcc97H HCC cell lines. Cell proliferation, wound healing, motility, invasion and adhesion capacities were examined to evaluate the inhibitory effect of DIOS on the metastasis of HCC cells. Cell viability was detected using an MTT assay in order to verify the inhibitory effect of DIOS on the proliferation of HCC cells. Cell migration was assessed using would healing and motility assays in order to verify the inhibitory effect of DIOS on the migration of HCC cells. Cell invasion and adhesion assays were performed in order to verify the inhibitory effect of DIOS on the invasion and adhesion of HCC cells.
3.Pharmacokinetic Profile of µSMIN Plus™, a new Micronized Diosmin Formulation, after Oral Administration in Rats.
Russo R, Mancinelli A, Ciccone M, Terruzzi F, Pisano C, Severino L. Nat Prod Commun. 2015 Sep;10(9):1569-72.
Diosmin is a naturally occurring flavonoid present in citrus fruits and other plants belonging to the Rutaceae family. It is used for the treatment of chronic venous insufficiency (CVI) for its pheblotonic and vaso-active properties, safety and tolerability as well. The aim of the current in vivo study was to investigate the pharmacokinetic profile of a branded micronized diosmin (µSMIN Plus™) compared with plain micronized diosmin in male Sprague-Dawley rats. After oral administration by gastric gavage, blood samples were collected via jugular vein catheters at regular time intervals from baseline up to 24 hours. Plasma concentrations were assessed by LC/MS. For each animal, the following pharmacokinetic parameters were calculated using a non-compartmental analysis: maximum plasma drug concentration (Cmax), time to reach Cmax (Tmax), area under the plasma concentration-time curve (AUC0-last), elimination half-life (t½), and relative oral bioavailability (%F).
4.Comparative Pharmacokinetics Study of Icariin and Icariside II in Rats.
Cheng T1, Zhang Y2, Zhang T3, Lu L4, Ding Y5, Zhao Y6. Molecules. 2015 Dec 1;20(12):21274-86. doi: 10.3390/molecules201219763.
To explore the pharmacokinetic properties of icariin (ICA) and icariside II (ICA II) following intragastric and intravenous administration in rats, a rapid and sensitive method by using ultra-performance liquid chromatography-tandem mass spectroscopy (UPLC-MS/MS) was developed and validated for the simultaneous quantification of ICA and ICA II in rat plasma. The quantification was performed by using multiple reaction monitoring of the transitions m/z 677.1/531.1 for ICA, 515.1/369.1 for ICA II and 463.1/301.1 for diosmetin-7-O-β-d-glucopyranoside (IS). The assay showed linearity over the concentration range of 1.03-1032 ng/mL, with correlation coefficients of 0.9983 and 0.9977. Intra- and inter-day precision and accuracy were within 15%. The lower limit of quantification for both ICA and ICA II was 1.03 ng/mL, respectively. The recovery of ICA and ICA II was more than 86.2%. The LC-MS/MS method has been successfully used in the pharmacokinetic studies of ICA and ICA II in rats.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cytochrome P450 Products


CFG920
(CAS: 1260006-20-9)

CFG920 is a Steroid 17-alpha-hydroxylase inhibitor originated by Novartis. It has potential antiandrogen and antineoplastic activities. It may inhibit cell prol...

VT-464 R enantiomer
(CAS: 1375603-38-5)

The R-enantiomer form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor.

CAS 201410-53-9 Talarozole

Talarozole
(CAS: 201410-53-9)

Talarozole, a retinoic acid metabolism blocking agent (RAMBA), is a potent and selective inhibitor of cytochrome P450 26 to treat dermatalogical diseases includ...

CAS 115575-11-6 Liarozole

Liarozole
(CAS: 115575-11-6)

This active molecular has a potential antineoplastic activity. As a retinoic acid metabolism blocking agent (RAMBA), liarozole inhibits P450-dependent ATRA-4-hy...

CAS 95-25-0 Chlorzoxazone

Chlorzoxazone
(CAS: 95-25-0)

Chlorzoxazone is a muscle-relaxing drug, and a probe for human liver cytochrome P-450IIE1.

CAS 24144-92-1 TMS

TMS
(CAS: 24144-92-1)

TMS is a selective, competitive inhibitor of cytochrome P450 1B1 which has a very high degree of selectivity for P450 1B1 versus both P450 1A1 (>50-fold) and P4...

CAS 10236-47-2 Naringin

Naringin
(CAS: 10236-47-2)

Naringin inhibits hepatic P-glycoprotein (P-gp) and some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug i...

CAS 851983-85-2 Galeterone

Galeterone
(CAS: 851983-85-2)

Galeterone (TOK-001 or VN/124-1) is a novel antiandrogen under development by Tokai Pharmaceuticals for the treatment of prostate cancer. It possesses a unique ...

VT-464 racemate
(CAS: 1375603-36-3)

The racemate form of VT-464, a non-steroidal compound, has been found to lead to the reduction of androgen through acting as a human CYP17 lyase inhibitor. IC50...

CAS 154229-19-3 Abiraterone

Abiraterone
(CAS: 154229-19-3)

Abiraterone blocks the synthesis of androgens by inhibiting CYP17A1. It is used to treat metastatic, castration-resistant prostate cancer.

CAS 50-52-2 Thioridazine

Thioridazine
(CAS: 50-52-2)

Thioridazine is an inhibitor of CYP1A2 and CYP3A2. It is a piperidine typical antipsychotic drug belonging to the phenothiazine drug group and was previously wi...

CAS 62-68-0 Proadifen Hydrochloride

Proadifen Hydrochloride
(CAS: 62-68-0)

Proadifen hydrochloride is a Cytochrome P450 inhibitor (IC50 = 19μM) and stimulate endothelial cell prostacyclin production.

CAS 870093-23-5 Talarozole

Talarozole
(CAS: 870093-23-5)

Talarozole, a retinoic acid metabolism blocking agent (RAMBA), is a potent and selective inhibitor of cytochrome P450 26 to treat dermatalogical diseases includ...

BMS-351
(CAS: 1370001-71-0)

BMS-351 is a selective and nonsteroidal CYP17A1 lyase inhibitor with good selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 has become a preclinical ca...

CAS 117620-77-6 3-Cyano-7-ethoxycoumarin

3-Cyano-7-ethoxycoumarin
(CAS: 117620-77-6)

3-Cyano-7-ethoxycoumarin, a kind of fluorogenic coumarin ether, is a fluorescent p450 substrate and used to confirm the effect of sorts of CYP450 enzymes.

CAS 1004316-88-4 Cobicistat

Cobicistat
(CAS: 1004316-88-4)

Cobicistat is a potent inhibitor of cytochrome P450 3A enzymes, including the important CYP3A4 subtype. It also inhibits intestinal transport proteins, increasi...

CAS 755013-59-3 Veledimex racemate

Veledimex racemate
(CAS: 755013-59-3)

Veledimex racemate is the racemate of veledimex. Veledimex is an orally active small molecule diacylhydrazine and controls the expression of the target gene.

CAS 40180-04-9 Tienilic Acid

Tienilic Acid
(CAS: 40180-04-9)

Tienilic acid is a heterocyclic derivative of phenoxyacetic acid that acts as a suicide substrate at the cytochrome P450 enzymes involved in drug metabolism. It...

VT-464
(CAS: 1610537-15-9)

VT-464, also called as Seviteronel, is an oral, non-steroidal, lyase-selective CYP17 inhibitor to reach Phase II clinical trials in Breast cancer in USA (PO). i...

CAS 54-36-4 Metyrapone

Metyrapone
(CAS: 54-36-4)

Metyrapone acts as a glucocorticoid synthesis inhibitor, blocks cortisol synthesis by inhibiting steroid 11β-hydroxylase in adrenal cortex (IC50 = 7.8 μM).

Chemical Structure

CAS 520-34-3 Diosmetin

Quick Inquiry

Verification code

Featured Items